KRAS and lung carcinoma: A second study aims to test the safety of RO5126766 at different doses for patients with advanced KRAS+ lung cancer who have previously received treatment with a programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) inhibitor (NCT03681483).